Big pharma thinks it has spotted its next big opportunity — an untreatable silent killer that affects millions of people.
In recent months, large drugmakers including Allergan, Gilead and Novartis have collectively spent billions of dollars acquiring or licensing medicines designed to treat a liver disease that few people have heard of — non-alcoholic steatohepatitis, or Nash.
This advanced form of fatty liver disease causes scarring and inflammation of the liver and is thought to affect more than 16m people in the US, according to Bernstein, the investment bank.
您已閱讀9%（567字），剩余91%（5682字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。